Proficio Capital Partners LLC Invests $719,000 in Simulations Plus, Inc. (NASDAQ:SLP)

Proficio Capital Partners LLC bought a new stake in Simulations Plus, Inc. (NASDAQ:SLP - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 25,770 shares of the technology company's stock, valued at approximately $719,000. Proficio Capital Partners LLC owned about 0.13% of Simulations Plus as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Conestoga Capital Advisors LLC grew its holdings in shares of Simulations Plus by 15.0% during the 4th quarter. Conestoga Capital Advisors LLC now owns 2,226,262 shares of the technology company's stock worth $62,090,000 after purchasing an additional 290,414 shares in the last quarter. Tributary Capital Management LLC grew its holdings in shares of Simulations Plus by 21.7% during the 4th quarter. Tributary Capital Management LLC now owns 396,093 shares of the technology company's stock worth $11,047,000 after purchasing an additional 70,526 shares in the last quarter. Royce & Associates LP grew its holdings in shares of Simulations Plus by 28.8% during the 3rd quarter. Royce & Associates LP now owns 237,416 shares of the technology company's stock worth $7,602,000 after purchasing an additional 53,092 shares in the last quarter. Stephens Inc. AR acquired a new stake in shares of Simulations Plus during the 4th quarter worth approximately $905,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Simulations Plus by 402.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company's stock worth $1,279,000 after purchasing an additional 32,002 shares in the last quarter. Institutional investors and hedge funds own 78.08% of the company's stock.

Remove Ads

Simulations Plus Stock Down 0.3 %

SLP traded down $0.09 during trading on Friday, hitting $28.23. The company's stock had a trading volume of 125,102 shares, compared to its average volume of 162,658. The firm's 50 day moving average price is $31.78 and its two-hundred day moving average price is $31.61. Simulations Plus, Inc. has a 12 month low of $24.00 and a 12 month high of $51.22. The stock has a market capitalization of $567.20 million, a price-to-earnings ratio of 70.58 and a beta of 0.89.

Insider Buying and Selling at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the transaction, the director now owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. The trade was a 0.58 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 19.40% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on SLP shares. Stephens started coverage on Simulations Plus in a report on Friday, November 15th. They set an "overweight" rating and a $39.00 price objective on the stock. William Blair reaffirmed an "outperform" rating on shares of Simulations Plus in a research note on Wednesday, January 8th. Finally, KeyCorp boosted their price target on Simulations Plus from $35.00 to $37.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Simulations Plus presently has a consensus rating of "Moderate Buy" and an average target price of $49.40.

Simulations Plus Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.